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Introduction
One of the earliest occurrences in organogenesis is the develop-
ment of the vascular system. The vascular system is first formed 
as a primitive vascular network by differentiation and assembly 
of  vascular  progenitor  cells.  Molecular  differences  between   
arterial and venous endothelial cells (ECs) become apparent at 
this stage before circulation begins (Wang et al., 1998; Adams 
et al., 1999; Zhong et al., 2001). Although acquisition of arterial 
and venous EC identities from progenitors is a crucial step   
for establishing the complete circulation system, cellular and 
molecular processes that regulate arterial–venous specification 
are not fully elucidated.
Notch is a single-pass transmembrane receptor known for 
its function in controlling cell fate decisions and creating bound-
aries through cell–cell communication (Lai, 2004). Ligand 
binding to Notch leads to cleavage and release of the Notch   
intracellular domain (NICD), and NICD translocates to the   
nucleus and associates with the transcription factor RBP-J   
(also called CSL, CBF-1 in mammals, Suppressor of Hairless   
[Su(H)] in Drosophila, and LAG-1 in Caenorhabditis elegans; 
Christensen et al., 1996; Kidd et al., 1998; Artavanis-Tsakonas 
et al., 1999). Notch (Notch 1, 4) and its cell surface ligands 
(Delta like-1 [Dll1], Dll4, and Jagged1 and 2) are expressed in 
arteries but not in veins (Villa et al., 2001; Sörensen et al., 2009). 
Genetic studies of Notch signaling components have shown that 
these arterial EC markers are essential for proper formation of 
the developing vasculature (Xue et al., 1999; Lawson et al., 
2001; Duarte et al., 2004; Krebs et al., 2004). Thus, Notch sig-
naling plays an important role in arterial specification.
Wnt/-catenin signaling regulates embryogenesis and is 
involved in the pathogenesis of a variety of diseases (Nusse, 
2005; Clevers, 2006; Grigoryan et al., 2008). Recent studies 
suggested that Wnt/-catenin signaling also plays a key role   
in vascular biology (Goodwin and D’Amore, 2002). Mice defi-
cient for Wnt2 displayed vascular abnormalities including   
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et al., 2000; Yamamizu et al., 2009). We also reported that activa-
tion of the adrenomedullin/cAMP pathway induced differentia-
tion of arterial ECs from Flk1
+ cells. Activation of the cAMP 
pathway induced Notch activation in differentiating ECs. Although 
inhibition of Notch signaling abolished arterial EC induction, 
activation of Notch using a NICD–estrogen receptor fusion pro-
tein together with VEGF treatment did not induce arterial ECs 
(Yurugi-Kobayashi et al., 2006). These results indicated that 
Notch signaling is essential but not sufficient for arterial EC in-
duction, suggesting that other factors are involved in this process.
In this study, we investigated signal transduction events 
downstream of the cAMP pathway with the use of our ES cell 
differentiation system and found novel molecular machinery for 
defective placental vasculature (Monkley et al., 1996). Knock-
out mice for the Wnt receptor gene, Frizzled-5, died in utero 
due to defects in yolk sac angiogenesis (Ishikawa et al., 2001). 
Defects of the -catenin gene in ECs caused aberrant vascular 
patterning and increased vascular fragility (Cattelino et al., 2003). 
Nevertheless, the role of Wnt/-catenin signaling in arterial–venous 
development is unknown.
We previously demonstrated that Flk1
+ (also designated as 
VEGF receptor 2) cells derived from embryonic stem (ES) cells 
serve as vascular progenitors and can constructively reproduce the 
early vascular organization processes including differentiation of 
both endothelial and mural cells (MCs; vascular smooth muscle 
cells and pericytes) and vascular structure formation (Yamashita 
Figure 1.  Inhibitory effect of PI3K inhibitor LY294002 on 
arterial EC induction from Flk1
+ cells. (A) Double-fluorescent   
staining for CD31 and ephrinB2 after a 3-d culture of 
Flk1
+ cells (Flk-d3). Top panels: CD31 (pan-ECs, red) and 
DAPI (blue). Bottom panels: EphB4-Fc (ephrinB2
+ arterial 
ECs, green) and DAPI (blue). Flk1
+ cells stimulated with 
VEGF alone (50 ng/ml; left panels), VEGF and 8bromo-
cAMP (0.5 mM; middle panels), or VEGF, 8bromo-cAMP, 
and a PI3K inhibitor, LY294002 (7.5 µM; right panels). 
Bars: 100 µm. (B) Flow cytometry for CD31 and CXCR4 
expression at Flk-d3. Percentages of CXCR4
+/CD31
+ ar-
terial ECs and CXCR4
/CD31
+ venous ECs in total ECs 
(CD31
+ cells) are indicated. (C) PI3K activity at Flk-d3. 
Flk1
+ cells stimulated with vehicle, VEGF, 8bromo-cAMP, 
VEGF and 8bromo-cAMP, or VEGF, 8bromo-cAMP, and 
LY294002 (7.5 µM; n = 3; **, P < 0.01 vs. vehicle; 
NS: not significant). (D) Double-fluorescent immunostain-
ing for cleaved Notch intracellular domain (NICD) and 
CD31 at Flk-d3. Left panels, CD31 (pan-ECs, red). Mid-
dle panels, cleaved NICD (green). Right panels, merged 
image. Flk1
+ cells stimulated with VEGF alone, VEGF and 
8bromo-cAMP, VEGF, 8bromo-cAMP and LY294002, or 
VEGF, 8bromo-cAMP, and a -secretase inhibitor, DAPT 
(2.5 µM). Bars: 100 µm.327 Arterial endothelial cell specification • Yamamizu et al.
smooth muscle actin [SMA]/Calponin/SM22), were selec-
tively induced (Yamashita et al., 2000; Yamamizu et al., 2009) 
when purified ES cell–derived Flk1
+ cells were cultured with 
VEGF and serum. Under these culture conditions, only these 
two cell types (i.e., ECs and MCs), but not blood cells such as 
CD45
+ cells, were specifically induced (Yamamizu et al., 2009). 
Most of the CD31
+ ECs induced with VEGF and serum had a 
venous phenotype, which did not express ephrin B2, an arterial 
EC marker. Simultaneous stimulation of VEGF and cAMP   
signaling by addition of a cAMP analogue, 8bromo-cAMP,   
successfully induced ephrinB2
+ arterial ECs, indicating that the 
cAMP pathway regulates arterial EC induction (Fig. 1 A; 
Yurugi-Kobayashi et al., 2006).
We then investigated the downstream targets of cAMP. 
First we examined various kinase inhibitors (Fig. S1). Among 
them, LY294002, a phosphatidylinositol-3 kinase (PI3K) inhib-
itor,  potently  and  specifically  inhibited  the  cAMP-elicited   
induction of ephrinB2
+ arterial ECs (ephrinB2
+/CD31
+), but not 
total  EC  (CD31
+)  appearance  from  Flk1
+  progenitor  cells   
arterial EC induction. That is, not single, but dual activation of 
Notch and -catenin signaling together with VEGF success-
fully reconstituted arterial EC induction from vascular progeni-
tors. RBP-J, NICD, and -catenin formed a protein complex 
specifically in arterial but not venous ECs both from ES cells 
and in vivo. Moreover, dual induction of NICD and -catenin 
enhanced promoter activity of target genes in vitro and arterial 
gene expression during in vivo angiogenesis in adults. Thus, 
Notch and -catenin signaling converge via formation of a   
single protein complex which should form a core molecular   
machinery that induces arterial fate in ECs.
Results
PI3K is involved in arterial EC induction 
downstream of cAMP
Previously, we reported that two vascular cell types, ECs (posi-
tive for CD31/vascular endothelial [VE]–cadherin/endothelial 
nitric oxide synthase [eNOS]/Claudin5) and MCs (positive for 
Figure 2.  Inhibitory effect of GSK3 on arterial EC differentiation. (A) Double-fluorescent staining for CD31 and ephrinB2 at Flk-d3. Top panels, CD31 
(pan-ECs, red) and DAPI (blue). Bottom panels, EphB4-Fc (ephrinB2
+ arterial ECs, green) and DAPI (blue). Flk1
+ cells stimulated with VEGF alone (50 ng/ml),   
VEGF and 8bromo-cAMP (0.5 mM), VEGF, 8bromo-cAMP, and LY294002 (7.5 µM), or VEGF, 8bromo-cAMP, LY294002, and a GSK3 inhibitor, Bio (100 nM).   
Bars: 100 µm. (B) Flow cytometry for CD31 and CXCR4 expression at Flk-d3. Percentages of CXCR4
+/CD31
+ arterial ECs and CXCR4
/CD31
+ 
venous ECs in total ECs (CD31
+ cells) are indicated. (C) Experimental system for GSK3 expression. ES cell line expressing constitutive active (CA) form 
or dominant-negative (DN) form of GSK3 by tetracycline-inducible expression system (Tet-Off) were established. Doxycycline (Dox) was added during 
the first 4.5 d of culture of ES cell differentiation to Flk1
+ cells. Subsequently, Flk1
+ cells were sorted by MACS and plated on type IV collagen-coated 
dishes, and cells were cultured in the presence or absence of 1 µg/ml Dox. (D and E) Induction of CA-GSK3. (F and G) Induction of DN-GSK3. 
(D and F) Double-fluorescent staining for CD31 and ephrinB2 at Flk-d3. Top panels, CD31 (pan-ECs, red) and DAPI (blue). Bottom panels, EphB4-Fc   
(ephrinB2
+ arterial ECs, green) and DAPI (blue). Flk1
+ cells were cultured with VEGF alone, or VEGF and 8bromo-cAMP, in the presence or absence of Dox. 
Bars: 200 µm. (E and G) Flow cytometry for CD31 and CXCR4 expression at Flk-d3. Percentages of CXCR4
+/CD31
+ arterial ECs and CXCR4
/CD31
+ 
venous ECs in total ECs (CD31
+ cells) are indicated.JCB • VOLUME 189 • NUMBER 2 • 2010   328
Figure 3.  Arterial EC induction by dual activation of -catenin and Notch signaling. (A) Experimental system for dual activation of Notch and -catenin 
signaling. ES cell lines carrying CA--catenin regulated by Tet-Off system, and a fusion protein of N1ICD and estrogen receptor (ER), NERT
OP, were 
established. CA--catenin was induced by depletion of Dox, and Notch activation was induced by nuclear translocation of NERT
OP with addition of   
4-hydrotamoxifen (OHT). 1 µg/ml Dox was added during the first 4.5 d of culture of ES cell differentiation to Flk1
+ cells. After Flk1
+ cells were sorted by 
MACS and plated on type IV collagen-coated dishes, cells were treated with or without Dox and/or OHT (150 ng/ml). (B and C) Activation of -catenin 
together with VEGF. (B) Double-fluorescent staining for CD31 and ephrinB2 at Flk-d3. Left panels, Dox treatment. Right panels, Dox free (expression of   
CA--catenin). (C) Flow cytometry for CD31 and CXCR4 expression at Flk-d3. Percentages of CXCR4
+/CD31
+ arterial ECs and CXCR4
/CD31
+ venous 
ECs in total ECs (CD31
+ cells) are indicated. (D–F) Dual activation of Notch and -catenin signaling. (D) Double-fluorescent staining for CD31 and ephrinB2 329 Arterial endothelial cell specification • Yamamizu et al.
CA-GSK3 expression in Flk1
+ progenitor cells inhibited arte-
rial EC induction by VEGF and cAMP treatment (Fig. 2, D and E). 
On the other hand, DN-GSK3 expression in Flk1
+ progenitor 
cells weakly induced arterial ECs with VEGF treatment alone 
(Fig. 2 F and G), indicating that GSK3 negatively regulates 
arterial EC induction downstream of PI3K.
Activation of -catenin and Notch signaling 
induces arterial ECs
Next, we investigated whether -catenin, a negatively regulated 
downstream target of GSK3 (Nusse, 2005), is involved in arte-
rial EC induction. We generated an ES cell line expressing CA-
-catenin regulated by the Tet-Off system (Fig. S3; Hirabayashi 
et al., 2004; Yamamizu et al., 2009). Flk1
+ cells were sorted and 
recultured with VEGF in the presence or absence of 1 µg/ml 
Dox (Dox
+ or Dox
; Fig. 3 A). CA--catenin expression (Dox
) 
together with VEGF stimulation showed almost no induction   
of ephrinB2
+ arterial ECs (Fig. 3 B) as well as CXCR4
+/
CD31
+ arterial ECs (Fig. 3 C), indicating that -catenin signal-
ing alone is not sufficient for arterial EC induction.
Previously we established an inducible Notch activation 
system in ES cells using a fusion protein (NERT
OP) of the intra-
cellular domain of murine Notch1 (N1ICD) and the estrogen 
receptor (ER), which allows regulated nuclear translocation of 
N1ICD with an ER ligand, 4-hydroxytamoxifen (OHT; Fig. 3 A; 
Schroeder et al., 2006; Yurugi-Kobayashi et al., 2006). We sub-
sequently generated an ES cell line expressing both the NERT
OP 
fusion protein and tetracycline-regulated CA--catenin. Activa-
tion of Notch by addition of 150 ng/ml OHT together with 
VEGF induced only a faint arterial EC induction, compatible 
with our previous results (Yurugi-Kobayashi et al., 2006). How-
ever,  remarkable  appearance  of  ephrinB2
+  ECs  was  clearly   
observed after dual activation of Notch and -catenin signaling 
by the addition of OHT and depletion of Dox, respectively, even 
in the absence of cAMP (Fig. 3 D). FACS analysis further dem-
onstrated that the dual activation of Notch and -catenin signal-
ing completely reproduced the effects of cAMP on arterial 
EC induction (Fig. 3, E and F). Moreover, though LY294002 
or a -secretase inhibitor, DAPT, almost completely abolished   
arterial EC induction by cAMP, the dual activation of Notch and 
-catenin signaling completely reversed their inhibitory effects 
(Fig. 3 G). These results indicate that the dual activation of 
Notch and -catenin is sufficient to reconstitute the roles of 
cAMP in arterial EC induction.
Cytoplasmic -catenin translocates into the nucleus where 
it forms a complex with transcription factors of the TCF/LEF 
family and activates target molecules (Orsulic and Peifer, 1996; 
Nusse, 2005). To investigate whether the TCF transcription factor 
(Fig. 1 A and Fig. S1). We further quantitatively evaluated arte-
rial EC induction at the cellular level with flow cytometry. We 
used a chemokine receptor, CXCR4, as an arterial EC marker 
(Tachibana  et  al.,  1998; Ara  et  al.,  2005; Yurugi-Kobayashi   
et al., 2006). CXCR4
/CD31
+ venous ECs were mainly in-
duced by VEGF treatment alone. CXCR4
+/CD31
+ arterial ECs 
were induced in the presence of 8bromo-cAMP together with   
VEGF. Addition of LY294002 almost completely inhibited 
CXCR4
+ arterial EC induction, but not total CD31
+ cell appear-
ance (Fig. 1 B).
PI3K is known as one of the downstream molecules of 
VEGF signaling in adult ECs (Dayanir et al., 2001; Shiojima 
and Walsh, 2002). Although VEGF treatment alone induced no 
significant activation of PI3K in Flk1
+ cells, treatments with 
8bromo-cAMP significantly activated PI3K (Fig. 1 C). These 
results indicated that cAMP signaling, but not VEGF, can acti-
vate PI3K in vascular progenitors or differentiating ECs and 
contributes to arterial EC induction.
Notch signaling is known to have important functions   
during arterial–venous specification (Xue et al., 1999; Lawson   
et al., 2001; Villa et al., 2001; Duarte et al., 2004; Krebs et al., 
2004; Sörensen et al., 2009). Previously we demonstrated that 
addition of 8bromo-cAMP together with VEGF induced Notch 
activation in differentiating ECs (Fig. 1 D and Fig. S2; Yurugi-
Kobayashi  et  al.,  2006).  Addition  of  LY294002  virtually   
abolished cAMP-induced Notch activation (Fig. 1 D), indi-
cating that PI3K acts downstream of cAMP to activate Notch 
signaling in differentiating ECs.
GSK3 is negatively involved in arterial  
EC induction
We previously reported in our ES cell system that Notch signal-
ing is essential but not sufficient for arterial EC induction (Yurugi-
Kobayashi et al., 2006). We next investigated other downstream 
targets of the cAMP and PI3K pathways involved in arterial   
EC  induction. When  activation  of  glycogen  synthase  kinase 
(GSK) 3, one of the downstream targets of PI3K (Cross et al., 
1995), was blocked by addition of a GSK3 inhibitor, Bio, the 
inhibitory effects of LY294002 on ephrinB2
+ arterial EC induc-
tion was partially restored (Fig. 2 A). The inhibitory effect of 
LY294002 on CXCR4
+/CD31
+ arterial EC appearance was also 
partially reversed by the addition of Bio (Fig. 2 B). We gener-
ated ES cell lines expressing constitutively active (CA) or   
dominant-negative (DN) mutants of GSK3 using a tetracycline-
regulatable system (Tet-Off; Fig. S3; Summers et al., 1999; 
Rommel et al., 2001; Yamamizu et al., 2009). We then induced 
expression of the CA- or DN-GSK3 in Flk1
+ cell cultures by 
depleting doxycycline (Dox), a tetracycline analogue (Fig. 2 C). 
at Flk-d3. Top panels, CD31 (pan-ECs, red) and DAPI (blue). Bottom panels, EphB4-Fc (ephrinB2
+ arterial ECs, green) and DAPI (blue). Flk1
+ cells were treated 
with VEGF alone (50 ng/ml), together with Dox
+ (control), Dox
+/OHT
+ (Notch activated), or Dox
/OHT
+ (dual activated) condition. VEGF and 8bromo-
cAMP (0.5 mM) treatment in Dox
+ condition is shown as positive control. Bars: 100 µm. (E) Flow cytometry for CD31 and CXCR4 expression. Percentages of 
CXCR4
+/CD31
+ arterial ECs and CXCR4
/CD31
+ venous ECs in total ECs (CD31
+ cells) are indicated. (F and G) Expression profile of CXCR4 in CD31
+ ECs 
by flow cytometry. Percentages of CXCR4
+ arterial ECs in total ECs are indicated. (F) VEGF treatment alone (blue line), VEGF and 8bromo-cAMP (red line), 
and VEGF together with dual activation of -catenin and Notch activation (Dox
-, OHT
+; green line) are shown. (G) VEGF treatment alone (blue line), VEGF 
and 8bromo-cAMP (red line), VEGF, 8bromo-cAMP, and LY294002 (7.5 µM; left panel), DAPT (2.5 µM; right panel, orange line), VEGF, 8bromo-cAMP, and 
LY294002 (left panel), or DAPT (right panel) together with dual activation of -catenin and Notch activation (Dox
-, OHT
+; green line) are shown.
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in both the mouse and human genome in neuropilin1, dll4, and 
cxcr4 genes (Fig. S4). ChIP assays demonstrated that although 
the RBP-J protein was present on these RBP-J binding sites in 
both arterial and venous ECs, NICD and -catenin formed a 
protein complex with RBP-J only in arterial ECs (Fig. 5 F). We 
further confirmed the functional relevance of the dual activation 
of NICD and -catenin on target gene expression in Flk1
+ cells. 
Compared with NICD alone, dual expression of NICD and   
-catenin synergistically increased Hes1 gene promoter activity 
by approximately threefold (n = 3; P < 0.002; Fig. 5 G). Taken 
together, these results suggest that Notch and -catenin signal-
ing converge into a single protein complex with RBP-J, NICD, 
and  -catenin  (arterial  protein  complex)  on  RBP-J  binding   
sites specifically in arterial ECs, and that this heterotrimeric   
arterial  protein  complex  synergistically  activates  target  gene   
expressions in Flk1
+ vascular progenitors and induces arterial 
EC specification.
The arterial protein complex is also formed 
in embryonic and adult vessels
We  purified  arterial  (CXCR4
+/CD31
+/CD45
)  and  venous 
(CXCR4
/CD31
+/CD45
) ECs from embryonic day (E) 11.5 
mouse embryos (Fig. 6 A) and performed ChIP assays for the 
RBP-J binding sites in ephrinb2, neuropilin1, dll4, hes1, and 
cxcr4 genes. Purified arterial and venous ECs showed distinct 
mRNA expression patterns of arterial and venous EC markers, 
respectively (Fig. 6 B). Similar to ECs derived from ES cells, 
the  arterial  protein  complex  (NICD/-catenin/RBP-J  protein 
complex) was formed on RBP-J binding sites of arterial marker 
genes specifically in arterial ECs, but not in venous ECs in the 
embryo (Fig. 6 C). Moreover, we investigated whether the arte-
rial protein complex is also formed in adult mice using isolated 
aorta and vena cava. Notch1 and 4 proteins were specifically 
detected in the aorta (Fig. 6 D). IP assays revealed that NICD 
and -catenin formed a protein complex only in the aorta   
(Fig. 6 E). ChIP assays further demonstrated that the arterial 
protein complex was evidently identified in the aorta rather than 
is involved in arterial EC induction, we generated an ES cell 
line expressing DN-TCF4 regulated by the Tet-Off system   
(Fig. S3; van de Wetering et al., 2002; Yamamizu et al., 2009). 
Even when we expressed DN-TCF4 in Flk1
+ vascular progeni-
tors, cAMP-elicited arterial EC induction was not affected   
(Fig. 4, A and B). Thus, TCF did not appear to be involved in the 
arterial specification process.
A protein complex of RBP-J, NICD, and  
-catenin is formed specifically in  
arterial ECs
We  further  investigated  how  Notch  and  -catenin  signaling   
pathways interact to induce arterial ECs. We first attempted to   
examine the expression and molecular interaction of these two 
molecules in purified arterial and venous ECs induced from ES 
cells (Fig. 5 A; Yurugi-Kobayashi et al., 2006). Purified arterial 
and venous ECs showed a distinct mRNA expression pattern   
of arterial EC markers (ephrinB2, Notch1, Dll4, Hes1, Alk1, 
CXCR4, and NRP1) and venous EC markers (NRP2 and COUP-
TFII), respectively (Fig. 5 B). Western blot analysis revealed 
that Notch1 and 4 protein expression was specifically detected 
in arterial ECs but not in venous ECs (Fig. 5 C), suggesting that 
cAMP regulates both Notch induction and activation. Further-
more, the NICD was present almost specifically in the nuclear 
fraction of arterial ECs but not in that of venous ECs. Although 
-catenin was observed in the nuclear fraction of both arterial 
and venous ECs, arterial ECs showed a higher nuclear -catenin 
expression than venous ECs (Fig. 5 D). Immunoprecipitation 
(IP) assays revealed that the arterial-expressed NICD formed a 
protein complex with -catenin (Fig. 5 E). We further confirmed 
the formation of a NICD/-catenin protein complex on several 
arterial genes by chromatin-IP (ChIP) assays. Recently, RBP-J 
binding sites in mouse ephrinb2 or hes1 genes were reported to 
regulate their expression in response to Notch activation (Grego-
Bessa et al., 2007; Shimizu et al., 2008). We further performed 
in silico investigations of RBP-J binding sites within other 
arterial-specific genes, and found conserved RBP-J binding sites 
Figure 4.  Effects of DN-TCF4 on arterial EC induction from 
Flk1
+ cells. (Top) Double-fluorescent staining for CD31 and 
ephrinB2 at Flk-d3. CD31 panels, CD31 (pan-ECs, red) 
and DAPI (blue). ephrinB2 panels, EphB4-Fc (ephrinB2
+  
arterial ECs, green) and DAPI (blue). Flk1
+ cells induced 
from DN-TCF4 ES cell line were cultured with VEGF alone 
(50 ng/ml) or VEGF and 8bromo-cAMP (0.5 mM), in 
the presence or absence of 1 µg/ml Dox. Bars: 100 µm. 
  (Bottom) Flow cytometry for CD31 and CXCR4 expression 
at  Flk-d3.  Percentages  of  CXCR4
+/CD31
+  arterial  ECs 
and  CXCR4
/CD31
+  venous  ECs  in  total  ECs  (CD31
+ 
cells) are indicated.331 Arterial endothelial cell specification • Yamamizu et al.
in adults, we examined in vivo angiogenesis using a gel plug 
assay (Kim et al., 2002). Adenoviral vectors for NICD and/or 
CA--catenin were mixed into Matrigel plugs with VEGF 
(100 ng/ml) and heparin (10 units/ml). Transgene products 
were successfully induced in gel plugs at 1 wk after trans-
plantation (Fig. 7 A). Formation of vascular structures and 
the presence of blood cells within the vascular lumen oc-
curred in gel plugs to a similar extent under all experimental 
conditions tested (Fig. 7 B). Although expression of a pan-EC 
the vena cava (Fig. 6 F). Together, these results indicate the   
existence of the same molecular interaction in both embryos 
and adults.
Dual activation of Notch and -catenin 
signaling enhances arterial gene expression 
during in vivo angiogenesis
Finally, to investigate whether Notch and -catenin signal-
ing is involved in arterial specification during angiogenesis 
Figure 5.  Arterial-specific formation of pro-
tein complex with RBP-J, NICD, and -catenin. 
(A)  Purification  of  arterial  and  venous  ECs 
from ES cells. CXCR4
+/CD31
+ cells at Flk-d3 
induced  by  VEGF  (50  ng/ml)  with  8bromo-
cAMP  (0.5  mM)  and  CXCR4
/CD31
+  cells 
induced by VEGF alone were purified as arte-
rial and venous ECs, respectively. (B) RT-PCR 
for mRNA expression of arterial and venous 
EC markers in purified arterial and venous ECs   
induced from ES cells as indicated in panel A.   
(C)  Western  blot  for  protein  expression  of 
Notch1 and Notch4 in purified arterial and 
venous  ECs.  U,  undifferentiated  ES  cells;  V,   
venous ECs; A, arterial ECs. (D) Nuclear lo-
calization  of  NICD  and  -catenin.  A  repre-
sentative  result  of  Western  blot  analysis  for   
NICD and -catenin using nuclear fraction of 
purified arterial and venous ECs. Anti-histone 
H3: nuclear fraction control. (E) Immunoprecip-
itation assay. Immunoblot with anti–-catenin 
antibody  for  total  cell  lysates  or  cell  lysates 
immunoprecipitated with anti-NICD antibody. 
N: negative control, immunoprecipitated with 
normal  rabbit-IgG  antibody.  (F)  ChIP  assays 
for RBP-J, NICD, and -catenin on RBP-J bind-
ing sites of arterial markers in ECs from ES 
cells.  Input:  PCR  products  generated  using 
DNA from nonimmunoprecipitated chromatin 
as a template. Negative control: immunopre-
cipitated  with  normal  rabbit-IgG  antibody. 
RBP-J,  NICD,  -catenin:  immunoprecipitated 
chromatin with antibodies for corresponding 
proteins. (G) Hes1 Luciferase reporter assay. 
A  Notch  signaling  reporter,  Hes1-Lucifearse 
plasmid was transiently transfected to MACS-
purified Flk1
+ cells together with CA--catenin 
and/or NERT
OP activation. After 24 h, the 
luciferase activities were measured (n = 3;   
*, P < 0.05; **, P < 0.01 vs. control or between 
corresponding values).JCB • VOLUME 189 • NUMBER 2 • 2010   332
Figure 6.  Formation of the arterial protein complex in the embryo and adult vessels. (A) Purification of arterial and venous ECs from the mouse embryo. 
Arterial ECs (CXCR4
+/CD31
+/CD45
) and venous ECs (CXCR4
/CD31
+/CD45
) were isolated from E11.5 embryos. (B) RT-PCR for mRNA expression 
of arterial and venous EC markers in purified arterial and venous ECs from E11.5 mouse embryo. (C) ChIP assays for RBP-J, NICD, and -catenin on RBP-J 
binding sites of arterial markers in ECs from embryos. (D) Western blot for Notch1 and Notch4 in isolated aorta and vena cava. (E) Immunoprecipitation 
assay for isolated aorta and vena cava. Immunoblot with anti–-catenin antibody for total cell lysates or cell lysates immunoprecipitated with anti-NICD 
antibody. (F) ChIP assays for RBP-J, NICD, and -catenin on RBP-J binding sites of arterial markers in the aorta and vena cava.
marker, VE-cadherin, was not altered, expression of the arte-
rial markers ephrinB2 and Neuropilin1 was significantly in-
creased in gel plugs only with the dual induction of NICD and 
CA--catenin (Fig. 7, C and D). These results indicate that dual 
activation of Notch and -catenin signaling also functions in 
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Figure 7.  Enhancement of arterial gene expression through dual activation of Notch and -catenin during in vivo angiogenesis. Matrigel containing VEGF 
(100 ng/ml), heparin (10 units/ml), and adenoviral vectors (vehicle [control], HA-tagged N1ICD [NICD], and/or CA--catenin) were injected subcutane-
ously in mice. After 7 d, the mice were sacrificed and plugs were excised. (A) Western blot for HA-tagged N1ICD and CA--catenin in recovered cells from 
Matrigel plugs. (B) Hematoxylin and eosin staining of Matrigel sections. Overall appearances were not different. Invasion of blood vessels with vascular 
lumen and blood cells were observed. Bars: 200 µm. (C) Representative result of Western blot for VE-cadherin, ephrinB2, and Neuropilin1 in recovered 
cells from Matrigel plugs. (D) Quantitative evaluation of VE-cadherin (left graph), ephrinB2 (middle graph), and Neuropilin1 (right graph) protein expres-
sion in Matrigels. Relative expression normalized with -actin expression is shown. (n = 3; *, P < 0.05 vs. control).JCB • VOLUME 189 • NUMBER 2 • 2010   334
linked to -catenin. When adherens junctions mature, tyrosine 
residues in VE-cadherin tend to be dephosphorylated and -catenin 
is partially released from the complex (Dejana et al., 1999), 
allowing nuclear translocation of -catenin and activation of 
downstream signaling cascades. As VE-cadherin and -catenin 
are broadly expressed in ECs and mice with EC-specific disrup-
tion of -catenin show broad vascular phenotypes (Cattelino et al., 
2003), -catenin should possess both common roles in ECs and 
specific roles in arterial ECs. Adrenomedullin, which is mainly 
secreted from vascular smooth muscle cells, activates the cAMP 
pathway and induces arterial ECs in the ES cell system (Yurugi-
Kobayashi et al., 2006). Many other factors, such as fluid shear 
stress, should be involved in cAMP activation in ECs. All of this 
signaling in blood vessels should finally converge into the sin-
gle  arterial  protein  complex  (NICD/-catenin/RBP-J  protein 
complex) and contribute to induce arterial ECs (Fig. 8).
In addition to induction of arterial ECs, Notch and -catenin 
could also be potentially involved in maintenance of the arterial 
EC phenotype. When activation of Notch and -catenin signal-
ing was ceased in arterial ECs from Flk-d3, ephrinB2 expression 
was attenuated and disappeared until Flk-d12 (Fig. S5). On the 
other hand, When Notch and -catenin signaling was activated 
Discussion
Here, we demonstrated that simultaneous activation of Notch 
and -catenin signaling can constructively reproduce the induc-
tion processes of arterial ECs from Flk1
+ vascular progenitors 
through the formation of an arterial-specific protein complex. 
cAMP, PI3K, Notch, and -catenin signaling interact and con-
verge  during  EC  differentiation  to  specify  arterial  cell  fate. 
These findings provide novel insights into vascular signaling 
necessary for cell differentiation and diversification as well as 
into molecular mechanisms of cell fate determination.
In ECs, Notch (Notch1, 4) activation can be induced by 
various Notch ligands, including Dll1, Dll4, and Jagged2, which 
are expressed by arterial ECs, and Jagged1, which is expressed 
in ECs and mural cells (Villa et al., 2001; Sörensen et al., 2009). 
All of this Notch signaling is considered to be mediated by 
the NICD and RBP-J transcription factor. On the other hand,   
-catenin signaling in ECs can be activated through Wnt ligands 
as well as VE-cadherin. Thus, Wnt ligands such as Wnt2, 5a, 
and 10b, expressed in fetal blood vessels, are involved in EC 
differentiation (Monkley et al., 1996; Goodwin and D’Amore, 
2002). VE-cadherin is heavily tyrosine phosphorylated and is 
Figure 8.  Molecular mechanisms of arterial EC specifica-
tion. cAMP signaling, which could be induced by adreno-
medullin, shear stress, and so on, activates Notch and 
-catenin signaling through PI3K (and GSK3) in vascular 
progenitors (as well as differentiating ECs). Notch and 
-catenin signaling subsequently converges into a single 
protein complex with RBP-J, NICD, and -catenin (arterial 
complex) on arterial genes. Notch signaling from Notch 
ligand  binding  and  -catenin  signaling  from  Wnt  and   
VE-cadherin should also participate in forming the com-
plex. The arterial complex should play a central role in 
the specification of arterial cell fate in ECs.335 Arterial endothelial cell specification • Yamamizu et al.
from Dr. J.R. Woodgett, Samuel Lunenfeld Research Institute, Toronto, Can-
ada; Rommel et al., 2001), and DN-TCF4 (a gift from Dr. H. Clevers,   
University Medical Center, Utrecht, Netherlands; van de Wetering et al., 
2002)  were  introduced  into  the  downstream  region  of  tetracycline  re-
sponsive  element  (TRE)–regulatable  CMV  promoter  of  Exchange  vector   
(Yamamizu  et  al.,  2009).  We  previously  generated  ES  cells  carrying   
recombination sites of loxP and a mutant loxP, loxP511, in ROSA locus and 
tetracycline-transactivator  gene  (EStTA-ROSA;  Yamamizu  et  al.,  2009). 
Stable ES cell lines that express the desired cDNA under the control of the 
TRE-regulatable CMV promoter were generated by introducing Exchange 
vectors and pBS185 (Cre expression vector) to EStTA-ROSA cells using 
mouse ES cell Nucleofector kit (Lonza). Hygromycin- and ganciclovir- 
resistant colonies were selected and subjected to further studies (cDNA 
EStTA cells; Yamamizu et al., 2009). For DN-TCF4–expressing ES cells, total 
hygromycin- and ganciclovir-resistant colonies were collected and used.   
Tet-inducible expression and/or function of these cDNAs were confirmed 
by Western blotting and Wnt/-catenin signaling reporter assays using   
TOP-FLASH TCF reporter plasmid (Millipore; Fig. S3, A–D).
An ES cell line carrying both tet-regulatable CA--catenin gene and 
OHT-regulated Notch activation system with NERT
OP, a fusion protein of 
N1ICD and ER (Yurugi-Kobayashi et al., 2006), was generated by intro-
ducing NERT
OP plasmid carrying puromycin-resistant gene to CA--catenin 
EStTA cells using mouse ES cell Nucleofector kit (Lonza). Cells were then 
plated on 10-cm dishes containing 1 µg/ml doxycycline (Dox
+). After 1 d, 
the medium was changed to Dox
+ medium containing 200 µg/ml hygro-
mycin and 1 µg/ml puromycin. Hygromycin- and puromycin-resistant colo-
nies were selected and subjected to further studies (CA--catenin/NERT
OP 
EStTA cells).
Cell culture
ES cell lines, D3, EStTA-ROSA, and various EStTA derivatives were main-
tained as described previously (Yurugi-Kobayashi et al., 2006; Yamamizu 
et al., 2009). Differentiation was induced in these ES cell lines using dif-
ferentiation medium (DM) (-minimal essential medium, MEM; Invitro-
gen) supplemented with 10% fetal calf serum (FCS; Japan Bioserum) and 
5 × 10
5 M 2-mercaptoethanol (2-ME; Invitrogen) as described previously 
(Yamashita et al., 2000; Yurugi-Kobayashi et al., 2006; Yamamizu et al., 
2009). In brief, undifferentiated ES cells were cultured on type IV colla-
gen-coated dishes without leukemia inhibitory factor at a cell density of 
0.75–10
3 cells/cm
2 for 96–108 h. Cultured cells were harvested and 
subjected to magnetic cell sorting (MACS) purification. Purified Flk1
+ cells 
were then plated onto type IV collagen-coated dishes (BD) at a density of 
0.75–10
4 cells/cm
2 in DM. After 3 d of Flk1
+ cell differentiation (Flk-d3), 
induced ECs were examined by immunohistochemistry and flow cytometric 
analyses. Various reagents were occasionally added to the Flk1
+ cell culture, 
including human VEGF165 (R&D Systems), 8-bromoadenosine-3, 5-cyclic 
monophosphate sodium salt (8-bromo-cAMP’ Nacalai Tesque), -secretase 
inhibitor, DAPT, PI3K inhibitor, LY294002, GSK3 inhibitor, Bio, Akt inhibi-
tor, TAT-Akt-inh, PKA inhibitor, PKI or H89, p38 inhibitor, SB202190, MEK   
inhibitor, PD98059, PKC inhibitor, PKC inhibitor, and PKC inhibitor 
(EMD). Dox was added to ES cells during the first 4.5 d of ES cell differen-
tiation culture for the tetracycline-regulated cDNA expression experiments. 
Subsequently, purified Flk1
+ cells were plated on type IV collagen-coated 
dishes and cultured in the presence or absence of 1 µg/ml Dox. 1 µg/ml 
Dox did not affect EC differentiation, proliferation, or arterial–venous spec-
ification in control ES cells (Yamamizu et al., 2009). For OHT-induced 
Notch activation, 150 ng/ml of OHT was added 24 h after Flk1
+ cell plat-
ing. OHT did not affect arterial–venous specification in control ES cells.
Immunocytochemistry
Immunostaining of cultured cells was conducted as described previously 
(Yurugi-Kobayashi et al., 2006, Yamamizu et al., 2009). ECs were fixed 
with 5% dimethyl sulfoxide/methanol. For double staining of ephrinB2 and 
CD31, fixed culture slides were incubated with EphB4-human immuno-
globulin (Ig) Fc portion chimeric protein (EphB4-Fc; 1:50; R&D Systems) 
followed  by  human  IgG  Fc  peroxidase-conjugated  goat  IgG  fraction 
(1:500; ICN Biomedicals, Inc.). TSA biotin system (PerkinElmer) was used 
to amplify the signal for EphB4-Fc staining. EphrinB2P
+P cells were visu-
alized with streptavidin/Alexa Fluor 488 conjugate (Invitrogen; Yurugi-
  Kobayashi et al., 2006). CD31
+ cells were stained with phycoerythrin 
(PE)-conjugated monoclonal antibody (mAb) for CD31 (Mec13.3; 1:300; 
BD). Cleaved Notch intracellular domain (NICD) staining was performed 
with TSA Biotin System using anti-cleaved Notch1 antibody (1:300; Cell 
Signaling  Technology),  followed  by  peroxidase-labeled  anti–rabbit  IgH   
antibody (1:500; Vector Laboratories; Yurugi-Kobayashi et al., 2006). 
at Flk-d3 in venous ECs induced by VEGF alone, ephrinB2 ex-
pression could still be induced (Fig. S5), suggesting that ECs at 
the early differentiation stage still possess a plasticity for arterial–
venous specification. The existence of the arterial protein com-
plex in the adult vessels (Fig. 6) and synergistic effect of dual 
activation of Notch and -catenin signaling on arterial gene 
expression during in vivo angiogenesis (Fig. 7) provide further 
supporting evidence that the complex should be involved in the 
induction as well as the maintenance of arterial phenotypes. Re-
cently, Shin et al. (2009) reported that activation of Notch or 
-catenin signaling during early mesoderm differentiation in 
the  chick  embryo  induces  separation  of  smooth  muscle  and 
blood/endothelial progenitor lineages. Notch and -catenin sig-
naling should play distinct roles in cell fate determination de-
pending on each differentiation stage.
Interaction of Notch and -catenin signaling has been 
reported in various contexts. Though Notch and -catenin signal-
ing pathways were reported to produce synergistic effects on 
maintenance of hematopoietic stem cells (Duncan et al., 2005), 
hair follicles (Estrach et al., 2006), and intestinal stem cells 
(Radtke and Clevers, 2005; van Es et al., 2005), direct molecular 
interaction of Notch and -catenin was not clear from these re-
ports. Direct interaction of Notch and -catenin has been reported 
in Drosophila, in which the Notch C-terminal region to the cdc10/
ankyrin repeats is associated with Armadillo/-catenin and nega-
tively  regulates  -catenin/TCF  transcription  (Hayward  et  al., 
2005). In our study, TCF4 was not involved in arterial specifica-
tion, and -catenin exerted its arterializing effect through a TCF-
independent manner. Recently, Shimizu et al. (2008) showed that 
the Notch/-catenin/RBP-J complex suppresses differentiation 
of neural precursor cells independent of TCF. The protein com-
plex that directly converges Notch and -catenin signaling may 
play a critical role in cell fate determination in various organs.
Until now, individual roles of VEGF, Flk1, PI3K, Notch, 
and -catenin have been suggested in various studies, namely, 
VEGF and Flk1 in EC differentiation (Sakurai et al., 2005), 
PI3K and -catenin in vascular formation (Monkley et al., 1996; 
Dayanir et al., 2001; Ishikawa et al., 2001; Goodwin and 
D’Amore, 2002; Shiojima and Walsh, 2002; Cattelino et al., 
2003), and Notch in arterial specification (Xue et al., 1999; 
Lawson et al., 2001; Villa et al., 2001; Zhong et al., 2001; 
Duarte et al., 2004; Krebs et al., 2004; Sörensen et al., 2009). 
We constructively reproduced the cellular processes of arterial 
EC induction in vitro, which can lead to integrate these signal-
ing pathways and offer comprehensive understanding of how 
these molecules interact during EC differentiation and arterial 
specification. The novel insights into the molecular machinery 
of cell differentiation and diversification would provide clues 
for clinical strategies with vascular-specific manipulation and 
drug discovery targeting ischemic disease and cancer.
Materials and methods
Generation of stable cell lines with inducible cDNAs
cDNA for CA--catenin (N90--catenin; a gift from Dr. Y. Gotoh, Univer-
sity of Tokyo, Tokyo, Japan; Hirabayashi et al., 2004), CA-GSK3 (S9A-
GSK; a gift from Dr. M.J. Birnbaum, University of Pennsylvania School   
of Medicine, Philadelphia, PA; Summers et al., 1999), DN-GSK3 (a gift JCB • VOLUME 189 • NUMBER 2 • 2010   336
to Grego-Bessa et al. (2007) and Shimizu et al. (2008), respectively   
(Table S2). Moreover, we performed in silico investigations of the cis-acting 
elements  within  various  reported  arterial-specific  genes  using  VISTA 
browser (Mayor et al., 2000) and ClustalW (Thompson et al., 1994). We 
analyzed  the  RBP-J  binding  sites  conserved  between  the  mouse  and   
human genomes in ±10 kb of each gene. We found conserved RBP-J bind-
ing sites in the neuropilin1, dll4, and cxcr4 genes (Fig. S4 and Table S2). 
PCR amplification was conducted with a variable number of cycles (94°C 
for 30 s, 60°C for 30 s, and 72°C for 30 s).
Luciferase reporter assay
FACS-purified Flk1
+ cells were transfected with a Notch signaling reporter, 
Hes1-Luciferase  plasmid  carrying  the  firefly  luciferase  gene  under  the   
control  of  the  Hes1  promoter  region  (467  to  +46;  a  gift  from  Drs.   
R. Kageyama and T. Ohtsuka, Kyoto University, Kyoto, Japan; Ohtsuka   
et al., 1999) using Lipofectamine 2000 (Invitrogen) according to the man-
ufacturer’s instruction. After 24 h, luciferase activity was assayed using a   
luminometer (Lumat LB 9507; Berthold Technologies). The luciferase activ-
ity was normalized with that of control Renilla luciferase.
Construction and preparation of adenovirus vectors
HA-tagged  N1ICD  (generated  by  deleting  the  ER  sequence  from  the 
NERT
OP plasmid; Yurugi-Kobayashi et al., 2006) or CA--catenin was 
introduced  into  pENTR  (Invitrogen),  and  LR  recombination  reactions 
were  performed  between  the  pAd/CMV/V5-DEST  (Invitrogen)  and 
pENTR  with  HA-tagged  NICD  or  CA--catenin  to  generate  full-length   
adenoviral vectors.
Plasmid  DNAs  encoding  the  full-length  adenoviral  vectors  were   
linearized and transfected into 293 cells using Lipofectamine 2000 (Invit-
rogen). The resultant adenovirus vectors were propagated by serial pas-
sages on 293 cells and purified by CsCl2 density gradient ultracentrifugation, 
as described previously (Ng and Graham, 2002).
In vivo Matrigel plug assay and cell recovery
In vivo induction of arterial ECs was evaluated with the Matrigel plug   
assay (Kim et al., 2002). VEGF (final concentration, 100 ng/ml; R&D Sys-
tems) and heparin (final concentration, 10 units/ml; Nacalai Tesque) were 
dissolved in BD Matrigels Matrix High Concentration Solution. Adenoviral 
vector solutions for vehicle, NICD, and/or CA--catenin were mixed with 
the Matrigel solution on ice (total 8 × 10
8 plaque-forming units [p.f.u.] of 
virus [20 µl]/500 µl Matrigel; control: 8 × 10
8 p.f.u. of vehicle; NICD:   
4 × 10
8 p.f.u. of NICD and 4 × 10
8 p.f.u. of vehicle; -catenin: 4 × 10
8 
p.f.u. of CA--catenin and 4 × 10
8 p.f.u. of vehicle; NICD + -catenin:   
4 × 10
8 p.f.u. of NICD and 4 × 10
8 p.f.u. of CA--catenin). Matrigel solu-
tion (500 µl) containing growth factors and adenovirus was injected sub-
cutaneously near the mid-abdomen of anesthetized nude mice, and the 
mice were sacrificed 7 d after injection. All animal experiments were per-
formed in accordance with the guidelines for Animal Experiments of Kyoto 
University, which conforms to the Guide for the Care and Use of Labora-
tory Animals in Japan. Gel plugs were excised and fixed in 4% para-
formaldehyde, subjected to an ethanol dehydration series, and embedded 
in paraffin. Serial sections were deparaffinized and stained with hematox-
ylin and eosin. Stained sections were photographed using a microscope 
(model BX51; Olympus) with 4× objectives, UPlanFLN (Olympus), and 
DP2-BSW software (Olympus). All images were taken at room tempera-
ture. For cell recovery, the excised Matrigel plugs were minced with a 
sterile scalpel, passed 10 times through an 18-gauge needle, treated with 
BD Cell Recovery Solution for 1 h at 4°C, centrifuged, and subjected to 
Western blotting.
Statistical analysis
Comparisons among values for all groups were performed with an analy-
sis of variance (ANOVA). At least three independent experiments were 
performed. A p-value less than 0.05 was considered significant. Values are 
reported as means ± SDs.
Online supplemental material
Fig. S1 shows pharmacological studies for cAMP downstream targets on 
arterial EC induction. Fig. S2 shows activation Notch signaling by cAMP 
together with VEGF. Fig. S3 shows generation of stable ES cell lines with 
inducible CA--catenin, CA-GSK3, or DN-TCF4. Fig. S4 shows in silico 
investigations  of  the  cis-acting  elements  within  arterial-specific  genes. 
Fig.  S5  shows  plasticity  for  arterial–venous  phenotypes  in  early  ECs.   
Table S1 shows the primer list for RT-PCR. Table S2 shows the primer list 
for  ChIP.  Online  supplemental  material  is  available  at  http://www.jcb 
.org/cgi/content/full/jcb.200904114/DC1.
Stained  cells  were  photographed  with  an  inverted  fluorescent  micro-
scope (Eclipse TE2000-U; Nikon) with 10× and 20× objectives, Plan 
Fluor (Nikon), a digital camera system, AxioCam HRc (Carl Zeiss, Inc.), 
and AxioVision software (Carl Zeiss, Inc.). All images were taken at 
room temperature.
PI3K activity assay
Flk1
+ cells (10
4 cells/ml) were incubated on 96-well plates and stimulated 
with vehicle, VEGF (50 ng/ml), 8-bromo-cAMP (0.5 mM), VEGF with 8-bromo-
cAMP, or VEGF with 8-bromo-cAMP and LY294002 (7.5 µM). After a   
3-d culture of Flk1
+ cells, PI3K activity was evaluated using FACE PI3   
Kinase p85 ELISA kit (Active Motif) according to the manufacturer’s instruc-
tions.  The  concentration  was  normalized  by  cell  numbers  stained  with 
crystal violet. PI3K activity was measured with a microplate reader (ARVO 
MX; PerkinElmer).
Cell purification and FACS analysis
After the induction of Flk1
+ cells, they were harvested and stained with   
allophycocyanin (APC)-conjugated AVAS12 antibody (Yamashita et al., 
2000). Flk1
+ cells were sorted with auto MACS (Miltenyi Biotec) using anti-
APC MicroBeads (Miltenyi Biotec) and recultured for EC differentiation. For 
the arterial and venous EC FACS analysis, cultured cells were harvested at 
Flk-d3 and stained with a combination of PE-conjugated anti-CD31 mAb 
(Mec13.3; BD) and biotin-conjugated anti-CXCR4 mAb (BD) followed by 
streptavidin-conjugated APC (BD), and then subjected to analysis using 
FACSVantage or FACSAria (BD). Arterial and venous ECs in vivo were iso-
lated from embryos at E11.5. Embryos were diced, digested with dispase II 
(Roche), and hemolyzed. Arterial and venous ECs negative for CD45 were 
obtained using FACSVantage or FACSAria.
RT-PCR
Total  RNA  was  isolated  from  arterial  and  venous  ECs  with  RNeasy   
(QIAGEN) according to the manufacturer’s instructions and reverse tran-
scribed with the SuperScript III First-Strand Synthesis System (Invitrogen). 
RT-PCR was performed as described previously (Yamashita et al., 2005) 
using the indicated primers (Table S1).
Subcellular proteome extraction and Western blotting
Sorted arterial and venous ECs were subjected to protein extraction ac-
cording to their subcelluar localization using the ProteoExtract Subcelluar 
Proteome Extraction kit (EMD). Nuclear extraction or total lysates were sub-
jected to SDS–PAGE using gradient gels (Atto Co.) followed by electropho-
retic  transfer  onto  nitrocellulose  membranes.  The  blots  were  incubated   
for 1 h in Blocking One blocking agents (Nacalai Tesque). Then, the mem-
branes  were  incubated  overnight  with  the  respective  first  antibodies 
(1:1,000) for -catenin (BD), NICD (Cell Signaling Technology), histone 
H3 (Abcam), Notch1 (Abcam), Notch4 (Santa Cruz Biotechnology, Inc.), 
ephrinB2 (R&D Systems), neuropilin1 (R&D Systems), and -actin (Sigma-
Aldrich).  Horseradish  peroxidase  (HRP)–conjugated  anti–mouse  Ig  anti-
body (Invitrogen), HRP-conjugated anti–goat Ig antibody (Invitrogen), or 
HRP-conjugated anti–rabbit Ig antibody (Vector Laboratories) were used as 
secondary antibodies (1:10,000). The Can Get Signal Immunoreaction 
Enhancer Solution kit (Toyobo) was used to enhance the signal. Immuno-
reactivity was detected with the Chemi-Lumi One Enhanced Chemilumines-
cence  kit  (Nacalai  Tesque).  Signal  intensity  was  calculated  with  Scion 
Image software (Scion Corp.).
Immunoprecipitation and chromatin immunoprecipitation assays
Arterial and venous EC cell lysates were subjected to immunoprecipita-
tion using Protein G HP SpinTrap (GE Healthcare) and anti-NICD anti-
body, and then immunoblotted with antibody specific to -catenin (see 
previous section).
Arterial and venous ECs were subjected to cross-linking with 3.7% 
formaldehyde. The aorta and vena cava were isolated from adult mice 
(8–10 wk old) and were also subjected to cross-linking with 3.7% formal-
dehyde, followed by the ChIP assay using a ChIP assay kit (Millipore). 
Chromatin was sheared to an average length of 0.4–1.0 kb. Antibodies 
to RBP-J (K0043; Tokusyu-meneki Laboratory, Tokyo, Japan), NICD (Cell 
Signaling Technology), and -catenin (BD) were used for immunoprecipi-
tation. PCR amplifications were performed in 20 µl with primers specific 
for the promoter analysis, as shown below. The sensitivity of the PCR   
amplifications was evaluated with serial dilutions of total DNA collected 
after sonication (input fraction). Amplified DNA was separated on 2% 
agarose gels and visualized with ethidium bromide. Sets of primers were 
used to amplify DNA sequences containing the conserved RBP-J binding 
sites (GTGGGAA) of the mouse ephrinB2 and Hes1 gene according   337 Arterial endothelial cell specification • Yamamizu et al.
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